Cardiovascular Complications of Carfilzomib

  • STATUS
    Recruiting
  • participants needed
    60
  • sponsor
    European Georges Pompidou Hospital
Send
Updated on 5 August 2020
See if I qualify
cardiovascular complications
carfilzomib
proteasome inhibitor

Summary

Cardiovascular toxicity of carfilzomib, a last generation proteasome inhibitor, is highly incident according to retrospective data. Prospective cohort study of patients initiated on carfilzomib.

Details
Condition Multiple Myeloma, Multiple Myeloma, Vascular Diseases, Vascular Diseases, Heart failure, Heart failure, Heart disease, Heart disease, Hypertension
Age 18years - 100years
Clinical Study IdentifierNCT04407858
SponsorEuropean Georges Pompidou Hospital
Last Modified on5 August 2020

Eligibility

 Yes No Not Sure

Inclusion Criteria

Intention to treat by Carfilzomib

Exclusion Criteria

History of carfilzomib treatment
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

cardiovascular complications
carfilzomib
proteasome inhibitor

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.